Top Calls: Catalent Delays Quarterly Report

The video discusses Catalent's recent decline in stock value due to productivity issues and delayed earnings reports. It highlights the company's past success with COVID-19 vaccine production and its future prospects in biologics and gene therapies. Speculation about a potential acquisition by Danaher is addressed, but Catalent currently remains independent.

What impact did the issues with the enterprise resource planning system have on Catalent?

What speculation exists regarding Catalent's independence as a company?